The Chamber of Commerce’s lawsuit is the first test of a barrage of lawsuits from the pharmaceutical industry and its allies over the new law.
A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare negotiate prices with ...
A federal court judge in Ohio denied Friday an attempt by the US Chamber of Commerce to immediately stop the Biden administration’s implementation of Medicare’s new drug price negotiation program.
Judge Michael Newman of the Southern District of Ohio issued a ruling denying a preliminary injunction sought by the Chamber ...
The Chamber of Commerce urged a federal judge on Friday to stop the new Medicare drug price negotiation program before Oct. 1 ...
The U.S. government's Medicare health insurance program can begin negotiating prices for some prescription drugs this fall under a new program, a federal judge ruled on Friday, vindicating one of ...
All of the companies had drugs that made the list of the first 10 medications to be subject to Medicare price negotiations. PhRMA, a leading drug industry trade group, and the US Chamber of ...
“Congress knew that withdrawing all products from federal healthcare programs would be economic suicide—not a ‘real option.’” – U.S. Chamber motion for preliminary injunction On August ...
The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major ...
Japanese drugmaker Astellas (OTCPK:ALPMF) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly ...
A major turning point in the battle to control ever-rising drug prices The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking ...
The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major ...
